Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959

Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, et al. Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959. Cancers. 2023; 15(4):1182. https://doi.org/10.3390/cancers15041182

Davidi, Shiri, Sara Jacobovitch, Anna Shteingauz, Antonia Martinez-Conde, Ori Braten, Catherine Tempel-Brami, Einav Zeevi, Roni Frechtel-Gerzi, Hila Ene, Eyal Dor-On, and et al. 2023. "Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959" Cancers 15, no. 4: 1182. https://doi.org/10.3390/cancers15041182

Davidi, S., Jacobovitch, S., Shteingauz, A., Martinez-Conde, A., Braten, O., Tempel-Brami, C., Zeevi, E., Frechtel-Gerzi, R., Ene, H., Dor-On, E., Voloshin, T., Tzchori, I., Haber, A., Giladi, M., Kinzel, A., Weinberg, U., & Palti, Y. (2023). Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959. Cancers, 15(4), 1182. https://doi.org/10.3390/cancers15041182